The use of ejaculation induction procedures in cancer patients

Dana A. Ohl, Mikkel Fode, Nancy Brackett, Charles M Lynne, Susanne A. Quallich, Jens Sønksen

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction Of the many causes of male infertility, ejaculatory dysfunction is relatively uncommon. Likewise, in cancer patients, it accounts for a small number of the total visits to practitioners. Nevertheless, there are certain situations in which the inability to ejaculate prevents fertility preservation or restoration in men before and after cancer treatment. This chapter will review the causes of ejaculation difficulties among this patient population, and potential treatments to circumvent the problem. Physiology of ejaculation During ejaculation sperm travel distally via the vasa deferentia, which join the seminal vesicles to form the ejaculatory ducts. These then enter the prostatic urethra just lateral to the verumontanum. The site of entry into the prostatic urethra is distal to the bladder neck and proximal to the external urethral sphincter, and this location is relevant in preventing retrograde ejaculation into the bladder, as the bladder neck contracts during ejaculation. The ejaculate that emerges from the urethra is a mixture of secretions from these various organs, with the majority coming from the seminal vesicles (approximately two-thirds) and the prostate. Sperm from the testes and mucoid bulbourethral gland secretions account for 1–2% of the volume [1]. After initial coagulation of the ejaculate, liquefaction is achieved by the proteolytic enzyme, prostate-specific antigen (PSA).

Original languageEnglish
Title of host publicationFertility Preservation in Male Cancer Patients
PublisherCambridge University Press
Pages243-248
Number of pages6
ISBN (Print)9780511997761, 9781107012127
DOIs
StatePublished - Jan 1 2010

Fingerprint

Ejaculation
Urethra
Urinary Bladder
Seminal Vesicles
Neoplasms
Spermatozoa
Bulbourethral Glands
Ejaculatory Ducts
Fertility Preservation
Male Infertility
Prostate-Specific Antigen
Contracts
Testis
Prostate
Peptide Hydrolases
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ohl, D. A., Fode, M., Brackett, N., Lynne, C. M., Quallich, S. A., & Sønksen, J. (2010). The use of ejaculation induction procedures in cancer patients. In Fertility Preservation in Male Cancer Patients (pp. 243-248). Cambridge University Press. https://doi.org/10.1017/CBO9780511997761.027

The use of ejaculation induction procedures in cancer patients. / Ohl, Dana A.; Fode, Mikkel; Brackett, Nancy; Lynne, Charles M; Quallich, Susanne A.; Sønksen, Jens.

Fertility Preservation in Male Cancer Patients. Cambridge University Press, 2010. p. 243-248.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ohl, DA, Fode, M, Brackett, N, Lynne, CM, Quallich, SA & Sønksen, J 2010, The use of ejaculation induction procedures in cancer patients. in Fertility Preservation in Male Cancer Patients. Cambridge University Press, pp. 243-248. https://doi.org/10.1017/CBO9780511997761.027
Ohl DA, Fode M, Brackett N, Lynne CM, Quallich SA, Sønksen J. The use of ejaculation induction procedures in cancer patients. In Fertility Preservation in Male Cancer Patients. Cambridge University Press. 2010. p. 243-248 https://doi.org/10.1017/CBO9780511997761.027
Ohl, Dana A. ; Fode, Mikkel ; Brackett, Nancy ; Lynne, Charles M ; Quallich, Susanne A. ; Sønksen, Jens. / The use of ejaculation induction procedures in cancer patients. Fertility Preservation in Male Cancer Patients. Cambridge University Press, 2010. pp. 243-248
@inbook{55d5717a359f41d4a49fe79c890bc5f8,
title = "The use of ejaculation induction procedures in cancer patients",
abstract = "Introduction Of the many causes of male infertility, ejaculatory dysfunction is relatively uncommon. Likewise, in cancer patients, it accounts for a small number of the total visits to practitioners. Nevertheless, there are certain situations in which the inability to ejaculate prevents fertility preservation or restoration in men before and after cancer treatment. This chapter will review the causes of ejaculation difficulties among this patient population, and potential treatments to circumvent the problem. Physiology of ejaculation During ejaculation sperm travel distally via the vasa deferentia, which join the seminal vesicles to form the ejaculatory ducts. These then enter the prostatic urethra just lateral to the verumontanum. The site of entry into the prostatic urethra is distal to the bladder neck and proximal to the external urethral sphincter, and this location is relevant in preventing retrograde ejaculation into the bladder, as the bladder neck contracts during ejaculation. The ejaculate that emerges from the urethra is a mixture of secretions from these various organs, with the majority coming from the seminal vesicles (approximately two-thirds) and the prostate. Sperm from the testes and mucoid bulbourethral gland secretions account for 1–2{\%} of the volume [1]. After initial coagulation of the ejaculate, liquefaction is achieved by the proteolytic enzyme, prostate-specific antigen (PSA).",
author = "Ohl, {Dana A.} and Mikkel Fode and Nancy Brackett and Lynne, {Charles M} and Quallich, {Susanne A.} and Jens S{\o}nksen",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511997761.027",
language = "English",
isbn = "9780511997761",
pages = "243--248",
booktitle = "Fertility Preservation in Male Cancer Patients",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - The use of ejaculation induction procedures in cancer patients

AU - Ohl, Dana A.

AU - Fode, Mikkel

AU - Brackett, Nancy

AU - Lynne, Charles M

AU - Quallich, Susanne A.

AU - Sønksen, Jens

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction Of the many causes of male infertility, ejaculatory dysfunction is relatively uncommon. Likewise, in cancer patients, it accounts for a small number of the total visits to practitioners. Nevertheless, there are certain situations in which the inability to ejaculate prevents fertility preservation or restoration in men before and after cancer treatment. This chapter will review the causes of ejaculation difficulties among this patient population, and potential treatments to circumvent the problem. Physiology of ejaculation During ejaculation sperm travel distally via the vasa deferentia, which join the seminal vesicles to form the ejaculatory ducts. These then enter the prostatic urethra just lateral to the verumontanum. The site of entry into the prostatic urethra is distal to the bladder neck and proximal to the external urethral sphincter, and this location is relevant in preventing retrograde ejaculation into the bladder, as the bladder neck contracts during ejaculation. The ejaculate that emerges from the urethra is a mixture of secretions from these various organs, with the majority coming from the seminal vesicles (approximately two-thirds) and the prostate. Sperm from the testes and mucoid bulbourethral gland secretions account for 1–2% of the volume [1]. After initial coagulation of the ejaculate, liquefaction is achieved by the proteolytic enzyme, prostate-specific antigen (PSA).

AB - Introduction Of the many causes of male infertility, ejaculatory dysfunction is relatively uncommon. Likewise, in cancer patients, it accounts for a small number of the total visits to practitioners. Nevertheless, there are certain situations in which the inability to ejaculate prevents fertility preservation or restoration in men before and after cancer treatment. This chapter will review the causes of ejaculation difficulties among this patient population, and potential treatments to circumvent the problem. Physiology of ejaculation During ejaculation sperm travel distally via the vasa deferentia, which join the seminal vesicles to form the ejaculatory ducts. These then enter the prostatic urethra just lateral to the verumontanum. The site of entry into the prostatic urethra is distal to the bladder neck and proximal to the external urethral sphincter, and this location is relevant in preventing retrograde ejaculation into the bladder, as the bladder neck contracts during ejaculation. The ejaculate that emerges from the urethra is a mixture of secretions from these various organs, with the majority coming from the seminal vesicles (approximately two-thirds) and the prostate. Sperm from the testes and mucoid bulbourethral gland secretions account for 1–2% of the volume [1]. After initial coagulation of the ejaculate, liquefaction is achieved by the proteolytic enzyme, prostate-specific antigen (PSA).

UR - http://www.scopus.com/inward/record.url?scp=84923432247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923432247&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511997761.027

DO - 10.1017/CBO9780511997761.027

M3 - Chapter

AN - SCOPUS:84923432247

SN - 9780511997761

SN - 9781107012127

SP - 243

EP - 248

BT - Fertility Preservation in Male Cancer Patients

PB - Cambridge University Press

ER -